Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Analysts

Key Points

• Analysts have a “Hold” consensus on Fate Therapeutics, with one sell, three hold and four buy ratings among eight firms. The average 12-month price target is $5.90, compared with the stock’s reported price of $2.31.
• Institutional investors own 97.54% of the company, while several investment firms recently initiated positions, each valued at roughly $29,000 to $35,000.
• Fate Therapeutics met quarterly EPS expectations at a loss of $0.25 per share and reported $2.08 million in revenue, slightly above estimates. However, the company continues to post substantial losses, including a negative 65.08% return on equity and a negative 1,941.09% net margin.

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have been assigned an average rating of "Hold" from the eight ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $5.90.

FATE has been the topic of several research analyst reports. HC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Fate Therapeutics in a research note on Monday, June 8th. Jefferies Financial Group set a $4.00 price target on shares of Fate Therapeutics in a research note on Tuesday, May 19th. Piper Sandler restated an "overweight" rating and set a $8.00 price objective (up from $6.00) on shares of Fate Therapeutics in a research report on Friday, August 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Fate Therapeutics in a report on Friday, August 7th. Finally, Wells Fargo & Company lifted their target price on shares of Fate Therapeutics from $2.50 to $3.50 and gave the stock an "equal weight" rating in a research report on Friday, August 14th.

Institutional Trading of Fate Therapeutics

Several large investors have recently modified their holdings of FATE. Callan Family Office LLC purchased a new stake in shares of Fate Therapeutics during the 2nd quarter valued at about $29,000. Bank of New York Mellon Corp purchased a new position in shares of Fate Therapeutics in the second quarter worth approximately $31,000. HB Wealth Management LLC purchased a new position in shares of Fate Therapeutics in the second quarter worth approximately $31,000. Focus Partners Advisor Solutions LLC bought a new stake in Fate Therapeutics during the second quarter valued at approximately $32,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in Fate Therapeutics during the second quarter valued at approximately $35,000. Institutional investors own 97.54% of the company's stock.

Fate Therapeutics Stock Performance

Fate Therapeutics stock opened at $2.31 on Monday. The firm has a market cap of $276.78 million, a price-to-earnings ratio of -2.20 and a beta of 2.54. The stock has a fifty day simple moving average of $2.61 and a two-hundred day simple moving average of $2.04. Fate Therapeutics has a 12 month low of $0.94 and a 12 month high of $3.23.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.25). Fate Therapeutics had a negative return on equity of 65.08% and a negative net margin of 1,941.09%.The firm had revenue of $2.08 million for the quarter, compared to the consensus estimate of $1.94 million. On average, equities research analysts forecast that Fate Therapeutics will post -1.06 EPS for the current fiscal year.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate's research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate's pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.